|
| Press Releases |
|
 |
|
| Wednesday, September 15, 2021 |
|
|
Hua and Sinopharm Announced Supply Chain Strategic Cooperation |
| On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099). more info >> |
|
| Thursday, August 19, 2021 |
|
|
华领医药公布2021年中期业绩 |
| 华领医药（「公司」，香港联交所股份代号：2552.HK），今天宣布公司及其附属公司截至2021年6月30日止，6个月（「报告期」）的综合业绩。 more info >> |
|
|
華領醫藥公佈2021年中期業績 |
| 華領醫藥（「公司」，香港聯交所股份代號：2552.HK），今天宣佈公司及其附屬公司截至2021年6月30日止，6個月（「報告期」）的綜合業績。 more info >> |
|
|
Hua Medicine Announces 2021 Interim Results |
| Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period"). more info >> |
|
| Friday, April 23, 2021 |
|
|
华领医药糖尿病首创新药多扎格列艾汀NDA获NMPA受理！为全球首个葡萄糖激酶激活剂 |
| 华领医药（「公司」，香港联交所股份代号：2552.HK），今天宣布，糖尿病首创新药多扎格列艾汀( dorzagliatin)递交的NDA申请已获国家药品监督管理局（NMPA）新药审评中心（CDE）受理。多扎格列艾汀成为全球范围内首个提交新药上市申请的葡萄糖激酶激活剂类（GKA）糖尿病治疗药物，并有望成为在中国首先上市的全球首创新药（FIC）。 more info >> |
|
|
華領醫藥糖尿病首創新藥多扎格列艾汀NDA獲NMPA受理！為全球首個葡萄糖激酶激活劑 |
| 華領醫藥（「公司」，香港聯交所股份代號：2552.HK），今天宣布，糖尿病首創新藥多扎格列艾汀(dorzagliatin)遞交的NDA申請已獲國家藥品監督管理局（NMPA）新藥審評中心（CDE）受理。 more info >> |
|
|
Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China - First Glucokinase Activator (GKA) Globally |
| Hua Medicine (the "Company", Stock Code: 2552.HK), today announced that the New Drug Application (NDA) for dorzagliatin for the treatment of Type 2 Diabetes (T2D) was accepted by the China National Medical Products Administration (NMPA). more info >> |
|
| Friday, March 19, 2021 |
|
|
Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's Dorzagliatin Readying for NDA Submission |
| Hua Medicine (2552.HK), today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2020 (the "Reporting Period"). more info >> |
|
|
华领医药公布2020年全年业绩 |
| 华领医药（「公司」，香港联交所股份代号：2552.HK），今天宣布公司及其附属公司截至2020年12月31日止经审核的全年业绩（「报告期」）。 more info >> |
|
|
華領醫藥公佈2020年全年業績 |
| 華領醫藥（「公司」，香港聯交所股份代號：2552.HK），今天宣佈公司及其附屬公司截至2020年12月31日止經審核的全年業績（「報告期」）。 more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
HKTDC unveils gifts, printing, packaging and licensing events
Apr 27, 2024 21:00: JST
|
|
|
HKTDC unveils gifts, printing, packaging and licensing events
Apr 27, 2024 20:00 HKT/SGT
|
|
|
Masverse Unveils Groundbreaking Blockchain Platform
Apr 27, 2024 02:40 HKT/SGT
|
|
|
Spritzer Scores Big with 'Meet the Red Legends' Event for Football Fans
Apr 27, 2024 00:00: JST
|
|
|
Spritzer Scores Big with 'Meet the Red Legends' Event for Football Fans
Apr 26, 2024 23:00 HKT/SGT
|
|
|
Announcing Mad About Marketing - A New Member of the Digital Sukoon Private Limited Family
Apr 26, 2024 22:25 HKT/SGT
|
|
|
FinTech Funding Continues to Surge as Second Edition of Dubai FinTech Summit Commences
Apr 26, 2024 21:10 HKT/SGT
|
|
|
汇聚科技有限公司公布截至二零二三年十二月三十一日止末期业绩
Apr 26, 2024 18:53 HKT/SGT
|
|
|
匯聚科技有限公司公佈截至二零二三年十二月三十一日止末期業績
Apr 26, 2024 18:43 HKT/SGT
|
|
|
UK advertising reports GBP36.6bn spend in 2023
Apr 26, 2024 18:30: JST
|
|
|
TIME Interconnect Technology Limited Announces Final Results For The Nine Months Ended 31 December 2023
Apr 26, 2024 18:26 HKT/SGT
|
|
|
UK advertising reports GBP36.6bn spend in 2023
Apr 26, 2024 17:30 HKT/SGT
|
|
|
CanSinoBIO CSO Shares the Latest Results of the Company's Globally Innovative Pneumococcal Vaccine
Apr 26, 2024 16:36: JST
|
|
|
CanSinoBIO CSO Shares the Latest Results of the Company's Globally Innovative Pneumococcal Vaccine
Apr 26, 2024 15:36 HKT/SGT
|
|
|
可持续发展三大支柱引领 海通恒信ESG必答卷高分亮相
Apr 26, 2024 15:28 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
